Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report details a specific corporate action regarding the repurchase of the company's own shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 1,500,000 Ordinary shares of 25 pence each.
- Purchase Date: July 5, 2011.
- Price Range: Highest price paid was 1,348.5 pence per share; lowest price paid was 1,340.5 pence per share.
- Treasury Holdings (Settled): 470,074,284 shares (8.39% of total issued share capital).
- Treasury Holdings (Including Unsettled): 473,804,284 shares (9.23% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,131,989,080 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,500,000 shares on July 5, 2011. Consequently, the company's treasury holdings increased to represent 8.39% of total issued share capital, with total voting rights held in treasury reaching 9.23% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The stated intent for the repurchased shares is to hold them in Treasury. The document notes that the number of shares in issue (excluding treasury) serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (470,074,284 settled) against the company's latest capitalization table.
- Confirm the percentage of total voting rights held in Treasury (9.23%) to assess potential dilution or control implications.
- Check the total shares in issue (5,131,989,080) to ensure accurate calculation of ownership thresholds for regulatory notifications.
- Review the price paid per share (1,340.5 to 1,348.5 pence) against market prices on July 5, 2011.